Ranbaxy wins on 2 additional Atorvastatin patents in Norway

39737 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy wins on 2 additional Atorvastatin patents in Norway

Ranbaxy wins on 2 additional Atorvastatin patents in Norway. Three of four patent rulings now favour Ranbaxy

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy puts Irish manufacturing unit on the block Ranbaxy eyeing Russia now Ranbaxy close to USD 100mln Russian buy ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 25/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (RLL) announced that a Norwegian court today handed down a favourable decision for Ranbaxy in its case against Pfizer, involving two patents on atorvastatin in Norway. Atorvastatin is a cholesterol-lowering drug which is marketed by Pfizer as Lipitor®.

The Oslo City Court sided with Ranbaxy by finding non-infringement of two of Pfizer's Norwegian patents (No. 177,566 and No. 180,199) covering particular intermediate compounds. Earlier in November 2005, the Norwegian Court had found Ranbaxy's atorvastatin product not to infringe one of Pfizer's process patents (No. 309,322) but to infringe another of Pfizer's patents (No. 177,706) covering a particular intermediate compound.

Ranbaxy has already appealed to the Norwegian Court of Appeals against the negative judgment on the one remaining intermediate compound patent. 

"This is a most important decision for Ranbaxy, as it significantly validates our position regarding the atorvastatin patents," said Jay Deshmukh, Senior Vice President, Global Intellectual Property for RLL. "We will continue to actively pursue all of our options in Norway and other markets in order to bring affordable atorvastatin to patients around the world."

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries

Sourced From: Ranbaxy Laboratories Ltd